Literature DB >> 17543849

Cholesterol synthesis prevails over absorption in metabolic syndrome.

Helena Gylling1, Maarit Hallikainen, Marjukka Kolehmainen, Leena Toppinen, Jussi Pihlajamäki, Hannu Mykkänen, Jyrki J Agren, Rainer Rauramaa, Markku Laakso, Tatu A Miettinen.   

Abstract

The objective of this study was to investigate cholesterol metabolism and its association with glucose metabolism and genetic regulation in metabolic syndrome. Overall, 74 subjects with clinically defined metabolic syndrome and sex and age-matched controls (n=74) were recruited. Cholesterol metabolism was assayed with serum non-cholesterol sterols, surrogate markers of synthesis, and fractional absorption of cholesterol and was related to variables of glucose and insulin action and to the common polymorphisms of the ABCG5 and ABCG8 genes. Serum squalene and non-cholesterol sterols were analyzed with gas-liquid chromatography (GLC) and presented as ratios to cholesterol. Also, synthesis marker/absorption marker ratios were calculated. The subjects with metabolic syndrome had higher cholesterol synthesis marker ratios, including squalene, and lower absorption marker ratios than controls. When adjusted with body mass index (BMI) and waist circumference, differences in some of the absorption markers (plant sterols), but not in the synthesis markers, disappeared. Plasma glucose, serum triglycerides, and homeostasis model assessment (HOMA) index were positively associated with cholesterol synthesis/absorption marker ratios (r=0.264 to 0.353, P<0.05 for all). In multivariate analysis, the serum squalene ratio was the best variable of those of cholesterol metabolism explaining the presence of metabolic syndrome. The polymorphisms of ABCG5 and ABCG8 genes did not differ between the cases and controls. In conclusion, cholesterol synthesis prevails over absorption in metabolic syndrome. The high serum squalene ratio turned out to be associated with the prevalence of metabolic syndrome. The perturbations of cholesterol metabolism seem to be related to abdominal obesity, and weight reduction might normalize cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543849     DOI: 10.1016/j.trsl.2006.11.012

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  16 in total

1.  Metabolite Signatures of Metabolic Risk Factors and their Longitudinal Changes.

Authors:  Xiaoyan Yin; Subha Subramanian; Christine M Willinger; George Chen; Peter Juhasz; Paul Courchesne; Brian H Chen; Xiaohang Li; Shih-Jen Hwang; Caroline S Fox; Christopher J O'Donnell; Pieter Muntendam; Valentin Fuster; Ivana Bobeldijk-Pastorova; Silvia C Sookoian; Carlos J Pirola; Neal Gordon; Aram Adourian; Martin G Larson; Daniel Levy
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

2.  Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study.

Authors:  Helena Gylling; Maarit Hallikainen; Jussi Pihlajamäki; Piia Simonen; Johanna Kuusisto; Markku Laakso; Tatu A Miettinen
Journal:  J Lipid Res       Date:  2010-05-01       Impact factor: 5.922

3.  The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality.

Authors:  Guenther Silbernagel; Guenter Fauler; Michael M Hoffmann; Dieter Lütjohann; Bernhard R Winkelmann; Bernhard O Boehm; Winfried März
Journal:  J Lipid Res       Date:  2010-03-14       Impact factor: 5.922

4.  Fatty acid- and cholesterol transporter protein expression along the human intestinal tract.

Authors:  Christiaan J Masson; Jogchum Plat; Ronald P Mensink; Andrzej Namiot; Wojciech Kisielewski; Zbigniew Namiot; Joachim Füllekrug; Robert Ehehalt; Jan F C Glatz; Maurice M A L Pelsers
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

5.  Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance.

Authors:  Zhih-Cherng Chen; Shyi-Jang Shin; Kung-Kai Kuo; Kun-Der Lin; Ming-Lung Yu; Pi-Jung Hsiao
Journal:  J Hum Genet       Date:  2008-06-26       Impact factor: 3.172

6.  Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Authors:  Eric J Niesor; David Kallend; Darren Bentley; John J P Kastelein; G Kees Hovingh; Erik S G Stroes
Journal:  Lipids       Date:  2014-10-04       Impact factor: 1.880

7.  Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease.

Authors:  Tadashi Ikegami; Hideyuki Hyogo; Akira Honda; Teruo Miyazaki; Katsutoshi Tokushige; Etsuko Hashimoto; Kazuo Inui; Yasushi Matsuzaki; Susumu Tazuma
Journal:  J Gastroenterol       Date:  2012-05-09       Impact factor: 7.527

Review 8.  The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease.

Authors:  Nadezhda S Sabeva; Jingjing Liu; Gregory A Graf
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

9.  Cholesterol metabolism and weight reduction in subjects with mild obstructive sleep apnoea: a randomised, controlled study.

Authors:  Maarit Hallikainen; Henri Tuomilehto; Tarja Martikainen; Esko Vanninen; Juha Seppä; Jouko Kokkarinen; Jukka Randell; Helena Gylling
Journal:  Cholesterol       Date:  2013-05-16

10.  Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease.

Authors:  Olga Renner; Dieter Lütjohann; Dominique Richter; André Strohmeyer; Silke Schimmel; Oliver Müller; Eduard F Stange; Simone Harsch
Journal:  BMC Gastroenterol       Date:  2013-02-13       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.